ClinicaliQ Trial Snapshot
- Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease — Recruiting • Diabetes / Metabolic • NCT04141592.
- What is being tested: The study investigates immune cell characteristics (tissue-resident and circulating), blood biomarkers, metabolic profiles, and microbiota composition (faecal and oral) to identify underlying pathological mechanisms in non-alcoholic fatty liver disease (NAFLD).
- Patient eligibility overview: The trial recruits adults with confirmed or suspected NAFLD across varying disease severity, typically excluding those with significant alcohol consumption, active viral hepatitis, or other chronic liver conditions that would confound results.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
Eligibility Snapshot
- : * Age ≥18 years * Confirmed non-alcoholic Fatty liver disease (diagnosed clinically, radiologically or histologically) * If diabetic, Diagnosed with Type 2 Diabetes Mellitus OR • Healthy Control: no diagnosis of any liver condition including NAFLD o NAFLD excluded by Fibroscan Controlled Attenuation Parameter (CAP) score of
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.